Mesoblast Limited

(NASDAQ:MESO)

Latest On Mesoblast Limited (MESO):

Date/Time Type Description Signal Details
2023-05-26 06:19 ESTNewsMesoblast Limited (MESO) Q3 2023 Earnings Call TranscriptN/A
2023-05-26 06:19 ESTNewsMesoblast GAAP EPS of -$0.025 beats by $0.13, revenue of $1.94M misses by $0.18MN/A
2023-05-04 20:51 ESTNewsMesoblast Has A Strong Upside PotentialN/A
2023-03-08 20:50 ESTNewsMesoblast stock surges ~10% on getting FDA review of graft versus host disease therapyN/A
2023-03-02 11:37 ESTNewsMesoblast Limited. (MESO) Q2 2023 Earnings Call TranscriptN/A
2023-02-28 14:47 ESTNewsMesoblast Limited 2023 Q2 - Results - Earnings Call PresentationN/A
2022-12-23 19:10 ESTNewsMesoblast and Oaktree extend availability of undrawn facilityN/A
2022-12-06 13:18 ESTNewsMesoblast stock falls 10% as Jefferies cuts rating to HoldN/A
2022-11-24 00:38 ESTNewsMesoblast Limited (MESO) Q1 2023 Earnings Call TranscriptN/A
2022-11-23 07:29 ESTNewsMesoblast GAAP EPS of -$0.0243 beats by $0.14, revenue of $1.5M misses by $1.82MN/A
2022-10-31 12:34 ESTNewsMesoblast reports operational and financial highlights for Q3N/A
2022-08-31 07:31 ESTNewsMesoblast Limited 2022 Q4 - Results - Earnings Call PresentationN/A
2022-08-31 07:31 ESTNewsMesoblast Limited (MESO) Q4 2022 Earnings Call TranscriptN/A
2022-08-31 07:31 ESTNewsMesoblast GAAP EPS of -$0.14, revenue of $10.21MN/A
2022-06-01 09:26 ESTNewsMesoblast GAAP EPS of -$0.03, revenue of $2MN/A
2022-02-02 13:18 ESTNewsNew medical chief at MesoblastN/A
2022-01-12 16:28 ESTNewsMesoblast’s rexlemestrocel-L results in durable pain reduction in degenerative disc diseaseN/A
2021-12-31 16:22 ESTNewsMesoblast to provide new data to FDA to support remestemcel-L BLA resubmissionN/A
2021-12-16 20:12 ESTNewsFDA’s OTAT in agreement pain reduction as primary endpoint in Mesoblast's Phase 3 programN/A
2021-12-14 07:58 ESTNewsMesoblast falls 8% after Novartis terminates deal prior to closingN/A
2021-12-06 08:59 ESTNewsMesoblast's rexlemestrocel-L shows treatment benefit in cardiovascular events in heart patientsN/A
2021-11-24 11:49 ESTNewsMesoblast EPS beats by $0.10, beats on revenueN/A
2021-11-22 16:32 ESTNewsMesoblast and Oaktree Capital refinance senior debt facilityN/A
2021-11-15 18:27 ESTNewsMesoblast's rexlemestrocel-l shows reduction in cardiovascular mortality, heart attacks and strokesN/A
2021-08-31 00:59 ESTNewsMesoblast EPS beats by $0.38N/A
2021-07-22 15:51 ESTNewsMesoblast reports FQ3 resultsN/A
2021-07-22 15:48 ESTNewsMesoblast provides update on rexlemestrocel-L in development for low back painN/A
2021-07-22 15:47 ESTNewsMesoblast reports respiratory function results of COVID-19 ARDS trialN/A
2021-07-22 15:47 ESTNewsMesoblast presents data showing mortality reduction of COVID-19 therapyN/A
2021-05-01 01:30 ESTNewsMESO, MOTS and SALM among premarket gainersN/A
2021-04-30 03:28 ESTNewsMesoblast's remestemcel-L reduces mortality by 46% in patients under age 65 with COVID-19 ARDSN/A
2021-04-08 03:05 ESTNewsMaxim upgrades Mesoblast to buy, sets $18 price targetN/A
2021-03-17 15:22 ESTAnalyst RatingThe Analyst Target Price has decreased from $14.5 to $13.7.Neutral
2021-03-16 23:50 ESTAnalyst RatingThe Analyst Target Price has decreased from $14.96 to $14.5.Neutral
2021-03-03 00:44 ESTNewsMesoblast announces a private placement of $110 millionN/A
2021-03-01 01:44 ESTEarnings EstimateAn EPS average of $0.03 is estimated for the quarter ending on March 31, 2021.Buy
2021-02-28 05:42 ESTFinancialsCompany financials have been released.Neutral
2021-02-17 14:54 ESTNewsMesoblast gains as remestemcel-l shows positive action in MIS-C post COVID-19N/A
2021-02-15 13:38 ESTAnalyst RatingThe Analyst Target Price has increased from $14.29 to $14.96.Buy
2021-02-12 12:18 ESTNewsMesoblast announces data from Phase 3 study in chronic back painN/A
2021-01-29 11:38 ESTNewsMesoblast issues FQ2 operational and financial updateN/A
2021-01-27 14:09 ESTAnalyst RatingThe Analyst Target Price has decreased from $14.96 to $14.29.Neutral
2021-01-19 22:20 ESTNewsMesoblast's Time May Be UpN/A
2021-01-11 12:34 ESTNewsMesoblast's rexlemestrocel-l reduces heart attacks, strokesN/A
2020-12-25 10:33 ESTAnalyst RatingThe Analyst Target Price has decreased from $16.45 to $14.96.Neutral
2020-12-24 16:56 ESTNewsMesoblast: The Future Looks BleakN/A
2020-12-24 02:40 ESTAnalyst RatingThe Analyst Target Price has increased from $14.96 to $16.45.Buy
2020-12-23 18:45 ESTAnalyst RatingThe Analyst Target Price has decreased from $15.39 to $14.96.Neutral
2020-12-20 22:34 ESTAnalyst RatingThe Analyst Target Price has decreased from $16.82 to $15.39.Neutral
2020-12-18 05:21 ESTNewsMesoblast shares plunge 32% after stem-cell therapy not likely to meet target for reducing mortality due to COVID-19N/A

About Mesoblast Limited (MESO):

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develop and commercialize cell therapy for the treatment of chronic low back pain. The company was founded in 2004 and is headquartered in Melbourne, Australia.

MESO Quotes by TradingView

See Advanced Chart

General

  • Name Mesoblast Limited
  • Symbol MESO
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 102
  • Fiscal Year EndJune
  • IPO Date2015-11-13
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.mesoblast.com
View More

Valuation

  • Forward PE 454.55
  • Price/Sales (Trailing 12 Mt.) 62.46
  • Price/Book (Most Recent Quarter) 2.28
  • Enterprise Value Revenue 70.47
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$0.29
  • Next Year EPS Estimate $0.17
  • Operating Margin -682%
  • Return on Assets -10%
  • Return on Equity -19%
  • Revenue 16.45 million
  • Earnings Per Share -$0.91
  • Revenue Per Share $0.15
  • Gross Profit 6.85 million
  • Quarterly Earnings Growth 1.6%
View More

Highlights

  • Market Capitalization 1.26 billion
  • EBITDA -78815000
  • Analyst Target Price $13.7
  • Book Value Per Share $4.42
View More

Share Statistics

  • Shares Outstanding 129.62 million
  • Shares Float 101.69 million
  • % Held by Insiders <1%
  • % Held by Institutions 2.87%
  • Shares Short 1.88 million
  • Shares Short Prior Month 2.82 million
  • Short Ratio 4.29
  • Short % of Shares Outstanding 2%
View More

Technicals

  • Beta 2.71
  • 52 Week High $21.28
  • 52 Week Low $3.12
  • 50 Day Moving Average 9.64
  • 200 Day Moving Average 12.23
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Mesoblast Limited (MESO) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Mesoblast Limited (MESO) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-02-26$N/A-$0.22-$0.15-43.61%
2020-09-302020-11-19$N/A-$0.21-$0.2619.04%
2020-06-302020-08-26$N/A-$0.30-$0.21-42.52%
2020-03-312020-05-27$12.08 million-$0.14-$0.1612.62%
2019-12-312020-02-26$2.21 million-$0.23-$0.13-71.64%
2019-09-302019-11-25$16.87 million-$0.06-$0.1970.27%
2019-06-302019-08-29$1.25 million-$0.21-$0.2724.04%
2019-03-312019-05-30$1.25 million-$0.25-$0.263.85%
2018-12-312019-02-20$1.87 million-$0.25-$0.23-8.7%
2018-09-302018-11-15$11.64 million-$0.20-$0.2311.52%
2018-06-302018-08-29$1.7 million-$0.22-$0.232.19%
2018-03-312018-05-30$1.07 million-$0.22-$0.22-1.59%
2017-12-312018-02-27$13.28 million$0.15-$0.20172.03%
2017-09-302017-11-14$1.11 million-$0.08-$0.2467.21%
2017-06-302017-08-29$473000-$0.32-$0.21-50.59%
2017-03-312017-05-24$820000-$0.12-$0.1935.26%
2016-12-312017-02-26$433000-$0.26-$0.20-34.92%
2016-09-302016-11-14$218000-$0.05-$0.2175.05%
2016-06-302016-08-24$26.62 million$0.64-$0.20423.54%
2016-03-312016-05-09$3.85 million-$0.04-$0.1263.7%
2015-12-312016-02-16$3.75 million-$0.31-$0.17-80.75%
2015-09-302015-12-16$7.25 million-$0.19

Mesoblast Limited (MESO) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Mesoblast Limited (MESO) Chart:

Mesoblast Limited (MESO) News:

Below you will find a list of latest news for Mesoblast Limited (MESO) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Mesoblast Limited (MESO) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2025-04-1710CALL0 01026.74TRUE00
2025-04-1720CALL0 0824.76TRUE00
2025-04-1730CALL0 0662.38TRUE00
2025-04-1747.8CALL0 0470.38TRUE00
2025-04-17512.2CALL0 0345.1TRUE00
2025-04-17611.4CALL0 2228.4TRUE00
2025-04-1779.1CALL0 0281.93TRUE00
2025-04-1787.4CALL0 32594.92TRUE00
2025-04-1794.82CALL0 7190.22TRUE00
2025-04-17104.15CALL0 359112.79TRUE00
2025-04-17113.1CALL0 37890.85TRUE00
2025-04-17122.5CALL0 46110.26TRUE00
2025-04-17130.75CALL120 14699.12FALSE-0.45-0.38
2025-04-17140.4CALL20 9091.78FALSE-0.5-0.56
2025-04-17150.28CALL54 157798.51FALSE-0.36-0.56
2025-04-17160.25CALL16 4196.03FALSE0.250
2025-04-17172.22CALL0 10799.86FALSE00
2025-04-17180.3CALL0 405117.88FALSE00
2025-04-17190.24CALL0 265165.37FALSE00
2025-04-17200.1CALL10 1242133.68FALSE0.10
2025-04-17212.3CALL0 39196.37FALSE00
2025-04-17220.7CALL5 9250.55FALSE0.70
2025-04-17231.7CALL0 6217FALSE00
2025-04-17240.15CALL0 12226.38FALSE00
2025-04-17250.35CALL0 7235.23FALSE00
2025-04-17260.3CALL0 10243.6FALSE00
2025-04-17270.2CALL0 1251.56FALSE00
2025-04-17280CALL0 0492.2FALSE00
2025-04-17290CALL0 0500.81FALSE00
2025-04-17301.5CALL0 400509.02FALSE00
2025-04-17310.45CALL0 1516.87FALSE00
2025-04-17321.5CALL0 1524.39FALSE00
2025-04-17331.4CALL0 6531.6FALSE00
2025-04-17341.25CALL0 1538.52FALSE00
2025-04-17351.45CALL0 2545.18FALSE00
2025-04-1710PUT0 01124.91FALSE00
2025-04-1720PUT0 00FALSE00
2025-04-1730PUT0 01499.95FALSE00
2025-04-1740PUT0 0758.21FALSE00
2025-04-1750.65PUT0 570343.96FALSE00
2025-04-1761.1PUT0 20694.6FALSE00
2025-04-1770.8PUT0 16228.2FALSE00
2025-04-1781PUT0 502160.14FALSE00
2025-04-1790.67PUT0 131264.43FALSE00
2025-04-17100.4PUT0 730197.08FALSE00
2025-04-17110.6PUT10 4102.38FALSE0.60
2025-04-17120.6PUT0 20131.95FALSE00
2025-04-17131.63PUT54 128100.63TRUE0.580.55
2025-04-17141.25PUT0 12387.6TRUE00
2025-04-17152.4PUT0 44189.28TRUE00
2025-04-17162.1PUT0 7130.09TRUE00
2025-04-17174.2PUT0 20117.01TRUE00
2025-04-17185.36PUT0 690120.52TRUE00
2025-04-17196.55PUT0 2270.68TRUE00
2025-04-17205.8PUT0 543207.88TRUE00
2025-04-17214.6PUT0 3308.45TRUE00
2025-04-17226.4PUT0 16124.58TRUE00
2025-04-17230PUT0 0301.36TRUE00
2025-04-172410.6PUT0 4203.87TRUE00
2025-04-17257PUT0 1173.48TRUE00
2025-04-17260PUT0 0197.01TRUE00
2025-04-17270PUT0 0373.04TRUE00
2025-04-17289.5PUT0 1211.48TRUE00
2025-04-17290PUT0 0201.31TRUE00
2025-04-17300PUT0 0224.75TRUE00
2025-04-17310PUT0 0384.32TRUE00
2025-04-17320PUT0 0219.36TRUE00
2025-04-17330PUT0 0224.95TRUE00
2025-04-17340PUT0 0405.27TRUE00
2025-04-17350PUT0 0280.34TRUE00
2025-05-1650CALL0 0264.56TRUE00
2025-05-1680CALL0 0143.56TRUE00
2025-05-1690CALL0 091.7TRUE00
2025-05-16100CALL0 066.57TRUE00
2025-05-16110CALL0 083.49TRUE00
2025-05-16121.7CALL3 092.97TRUE1.70
2025-05-16130CALL0 0121.6FALSE00
2025-05-16140CALL0 0110.01FALSE00
2025-05-16150CALL0 098.49FALSE00
2025-05-16160CALL0 098.22FALSE00
2025-05-16170CALL0 0150.93FALSE00
2025-05-16180CALL0 0138.01FALSE00
2025-05-16190.35CALL0 193.43FALSE00
2025-05-16200CALL0 0143.88FALSE00
2025-05-16250CALL0 0210.41FALSE00
2025-05-1650PUT0 0335.26FALSE00
2025-05-1680PUT0 0179.71FALSE00
2025-05-1690PUT0 0133.09FALSE00
2025-05-16100.57PUT0 278.43FALSE00
2025-05-16111PUT2 091.15FALSE10
2025-05-16121.6PUT6 097.27FALSE1.60
2025-05-16132.33PUT13 3104.86TRUE2.330
2025-05-16142.1PUT0 14103.06TRUE00
2025-05-16150PUT0 062.97TRUE00
2025-05-16163.56PUT0 164.86TRUE00
2025-05-16170PUT0 0133.33TRUE00
2025-05-16180PUT0 0100.49TRUE00
2025-05-16190PUT0 099.52TRUE00
2025-05-16200PUT0 0159.46TRUE00
2025-05-16250PUT0 0251.15TRUE00
2025-07-18315CALL0 2255.33TRUE00
2025-07-18512.3CALL0 1279.37TRUE00
2025-07-1860CALL0 0106.55TRUE00
2025-07-18710.8CALL0 50112.49TRUE00
2025-07-1885.75CALL0 572.87TRUE00
2025-07-1899.5CALL0 2590.11TRUE00
2025-07-18104.2CALL0 50396.97TRUE00
2025-07-18114.2CALL0 4289.77TRUE00
2025-07-18123.3CALL0 75897.54TRUE00
2025-07-18132.44CALL50 15190.94FALSE2.440
2025-07-18144.4CALL0 86100.35FALSE00
2025-07-18151.65CALL64 270595.75FALSE1.650
2025-07-18162.4CALL0 116492.34FALSE00
2025-07-18171.4CALL0 10892.3FALSE00
2025-07-18181.68CALL0 5196.24FALSE00
2025-07-18191.48CALL0 53675.87FALSE00
2025-07-18200.63CALL43 393489.21FALSE0.630
2025-07-18210.82CALL0 1892.76FALSE00
2025-07-18221.9CALL0 8194.79FALSE00
2025-07-18231.4CALL0 10880FALSE00
2025-07-18240.4CALL1 504394.29FALSE0.40
2025-07-18251.16CALL0 994.65FALSE00
2025-07-18260.7CALL0 792.55FALSE00
2025-07-18270.3CALL65 16597.69FALSE-0.1-0.25
2025-07-18282CALL0 192.18FALSE00
2025-07-18290CALL0 089.73FALSE00
2025-07-18300.8CALL0 2589.27FALSE00
2025-07-18311.73CALL0 194.8FALSE00
2025-07-18320.2CALL25 26102.67FALSE0.20
2025-07-18331.4CALL0 496.3FALSE00
2025-07-18341.3CALL0 2104.61FALSE00
2025-07-18350.55CALL0 296.88FALSE00
2025-07-1830PUT0 0217FALSE00
2025-07-1851.05PUT0 2127.49FALSE00
2025-07-1861.1PUT0 8107.98FALSE00
2025-07-1871.1PUT0 9100.14FALSE00
2025-07-1880.75PUT0 0125.36FALSE00
2025-07-1890.95PUT0 12120.35FALSE00
2025-07-18100.9PUT0 58101.98FALSE00
2025-07-18111.8PUT1 494.75FALSE1.80
2025-07-18121.7PUT0 13103.58FALSE00
2025-07-18132.58PUT0 52100.89TRUE00
2025-07-18143PUT0 4499.22TRUE00
2025-07-18153.6PUT0 1233100.55TRUE00
2025-07-18164.34PUT0 41117.54TRUE00
2025-07-18176PUT0 19106.77TRUE00
2025-07-18186.4PUT0 703102.19TRUE00
2025-07-18190PUT0 093.66TRUE00
2025-07-18206.22PUT0 099.64TRUE00
2025-07-18216.01PUT0 10109.86TRUE00
2025-07-18220PUT0 0121.93TRUE00
2025-07-18230PUT0 0115.27TRUE00
2025-07-18240PUT0 0112.23TRUE00
2025-07-18259PUT0 3126.69TRUE00
2025-07-18260PUT0 0120.56TRUE00
2025-07-18270PUT0 0112.42TRUE00
2025-07-18280PUT0 0122.3TRUE00
2025-07-18290PUT0 0119.42TRUE00
2025-07-18300PUT0 0111.26TRUE00
2025-07-18310PUT0 0132.34TRUE00
2025-07-18320PUT0 0106.4TRUE00
2025-07-18330PUT0 0120.1TRUE00
2025-07-18340PUT0 0122.85TRUE00
2025-07-18350PUT0 0144.08TRUE00
2025-10-1730CALL0 0168.17TRUE00
2025-10-1750CALL0 0135.82TRUE00
2025-10-1786.1CALL0 295.83TRUE00
2025-10-1796.45CALL0 378.53TRUE00
2025-10-17106.1CALL0 788.96TRUE00
2025-10-17115.09CALL0 197.17TRUE00
2025-10-17120CALL0 093.83TRUE00
2025-10-17134.14CALL0 2691.69FALSE00
2025-10-17143.2CALL1 791.37FALSE3.20
2025-10-17152.5CALL2 13193.54FALSE-0.7-0.22
2025-10-17160CALL0 092.73FALSE00
2025-10-17172.97CALL0 196.75FALSE00
2025-10-17183.9CALL0 5093.82FALSE00
2025-10-17192.46CALL0 591.63FALSE00
2025-10-17201.5CALL5 172393.22FALSE1.50
2025-10-17210CALL0 092.12FALSE00
2025-10-17221.25CALL1 793.62FALSE1.250
2025-10-17232.25CALL0 20091.57FALSE00
2025-10-17250.97CALL1 294.39FALSE0.970
2025-10-17301.1CALL0 283.77FALSE00
2025-10-1730PUT0 0171.76FALSE00
2025-10-1750PUT0 0105.19FALSE00
2025-10-1780PUT0 0104.09FALSE00
2025-10-1790PUT0 090.58FALSE00
2025-10-17102.27PUT2 0104.35FALSE2.270
2025-10-17112.65PUT2 098.56FALSE2.650
2025-10-17122.9PUT0 1100.19FALSE00
2025-10-17133.2PUT0 66100.45TRUE00
2025-10-17144.3PUT1 16101.04TRUE4.30
2025-10-17154.5PUT0 20099.29TRUE00
2025-10-17160PUT0 099.53TRUE00
2025-10-17170PUT0 0100.42TRUE00
2025-10-17180PUT0 0109.13TRUE00
2025-10-17197.86PUT0 098.9TRUE00
2025-10-17200PUT0 0105.28TRUE00
2025-10-17210PUT0 0102.49TRUE00
2025-10-17220PUT0 0106.74TRUE00
2025-10-17230PUT0 098.25TRUE00
2025-10-17250PUT0 096.72TRUE00
2025-10-17300PUT0 0111.59TRUE00
2026-01-160.51CALL15 160TRUE00
2026-01-1610CALL0 00TRUE00
2026-01-161.50CALL0 00TRUE00
2026-01-1621.67CALL30 4600TRUE00
2026-01-162.50.5CALL148 26090TRUE00
2026-01-1631CALL0 50TRUE00
2026-01-1640CALL0 00TRUE00
2026-01-1651.4CALL30 4610TRUE00
2026-01-160.50PUT0 00FALSE00
2026-01-1610PUT0 00FALSE00
2026-01-161.50PUT0 00FALSE00
2026-01-1620PUT0 00FALSE00
2026-01-162.50PUT0 00FALSE00
2026-01-1630PUT0 00FALSE00
2026-01-1640PUT0 00FALSE00
2026-01-1650PUT0 00FALSE00
2030-12-18100.2CALL456 3400TRUE-3.3-0.94
2030-12-18250PUT 0TRUE00

Latest MESO Trades:

Date Shares Price
Jun 13, 2022 7:54 PM EST100$2.645
Jun 13, 2022 7:54 PM EST100$2.645
Jun 13, 2022 7:55 PM EST100$2.64
Jun 13, 2022 7:57 PM EST186$2.66
Jun 13, 2022 7:57 PM EST14$2.66

Mesoblast Limited (MESO) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-07-026-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020031530/0001564590-20-031530-index.htm
2020-01-30SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1345099/000119312520019148/0001193125-20-019148-index.htm
2020-07-27S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1345099/000121390020018628/0001213900-20-018628-index.htm
2020-05-26DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1345099/000134509920000001/0001345099-20-000001-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1345099/000142284920000077/0001422849-20-000077-index.htm
2019-09-066-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019034209/0001564590-19-034209-index.htm
2019-09-0920-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1345099/000156459019034304/0001564590-19-034304-index.htm
2019-09-116-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019034483/0001564590-19-034483-index.htm
2019-10-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019036315/0001564590-19-036315-index.htm
2019-10-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019036431/0001564590-19-036431-index.htm
2019-10-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019036737/0001564590-19-036737-index.htm
2019-10-226-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019037256/0001564590-19-037256-index.htm
2019-11-016-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019039260/0001564590-19-039260-index.htm
2019-11-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019041204/0001564590-19-041204-index.htm
2019-11-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019044600/0001564590-19-044600-index.htm
2019-11-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019044601/0001564590-19-044601-index.htm
2019-11-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019044825/0001564590-19-044825-index.htm
2019-12-126-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019045775/0001564590-19-045775-index.htm
2019-12-246-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019046754/0001564590-19-046754-index.htm
2020-01-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020000984/0001564590-20-000984-index.htm
2020-01-226-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020001658/0001564590-20-001658-index.htm
2020-02-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020003090/0001564590-20-003090-index.htm
2020-02-066-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020003512/0001564590-20-003512-index.htm
2020-02-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020004688/0001564590-20-004688-index.htm
2020-02-266-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020006501/0001564590-20-006501-index.htm
2020-02-286-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020007597/0001564590-20-007597-index.htm
2020-03-116-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020009861/0001564590-20-009861-index.htm
2020-03-206-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020011865/0001564590-20-011865-index.htm
2020-03-256-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020012613/0001564590-20-012613-index.htm
2020-04-026-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020014830/0001564590-20-014830-index.htm
2020-04-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020015584/0001564590-20-015584-index.htm
2020-04-096-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020016005/0001564590-20-016005-index.htm
2020-04-206-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020017344/0001564590-20-017344-index.htm
2020-04-246-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020018322/0001564590-20-018322-index.htm
2020-05-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020020611/0001564590-20-020611-index.htm
2020-05-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020022226/0001564590-20-022226-index.htm
2020-05-156-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020025586/0001564590-20-025586-index.htm
2020-05-196-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020026055/0001564590-20-026055-index.htm
2020-05-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020026914/0001564590-20-026914-index.htm
2020-05-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020027408/0001564590-20-027408-index.htm
2020-05-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020027410/0001564590-20-027410-index.htm
2020-06-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020028116/0001564590-20-028116-index.htm
2020-06-186-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020029698/0001564590-20-029698-index.htm
2020-06-266-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020030668/0001564590-20-030668-index.htm
2020-07-026-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020031530/0001564590-20-031530-index.htm
2020-07-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020031863/0001564590-20-031863-index.htm
2020-07-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020032147/0001564590-20-032147-index.htm
2020-07-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020033456/0001564590-20-033456-index.htm
2020-08-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020035263/0001564590-20-035263-index.htm
2020-08-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020038657/0001564590-20-038657-index.htm
2020-08-126-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020039445/0001564590-20-039445-index.htm
2020-08-176-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020040358/0001564590-20-040358-index.htm
2020-08-256-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020041082/0001564590-20-041082-index.htm
2020-08-316-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020041869/0001564590-20-041869-index.htm
2020-09-0320-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1345099/000156459020042401/0001564590-20-042401-index.htm
2020-09-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020042407/0001564590-20-042407-index.htm
2020-09-086-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020042713/0001564590-20-042713-index.htm
2020-09-166-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020043641/0001564590-20-043641-index.htm
2020-09-176-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020043751/0001564590-20-043751-index.htm
2020-10-056-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020045777/0001564590-20-045777-index.htm
2020-10-156-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020046432/0001564590-20-046432-index.htm
2020-10-236-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020047335/0001564590-20-047335-index.htm
2020-10-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020048488/0001564590-20-048488-index.htm
2020-11-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020049709/0001564590-20-049709-index.htm